Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1GuruFocus · Oct 14, 2026
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis ConferenceGuruFocus · Oct 9, 2026
Head-To-Head Contrast: IMAX (NYSE:IMAX) versus iHuman (NYSE:IH)Defense World · Oct 5, 2026
iHuman Inc. Announces Second Quarter 2026 Unaudited Financial ResultsPRNewsWire · Sep 29, 2026
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of LifeGuruFocus · Sep 9, 2026
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1GuruFocus · Aug 24, 2026Operating within the People's Republic of China, iHuman Inc. specializes in delivering educational resources aimed at fostering cognitive growth. Their offerings reach a broad audience, encompassing individual consumers, early learning institutions, and wholesale distributors. A significant portion of their portfolio consists of interactive and self-guided digital applications.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 29, 2026 | $0.02 | -$0.05 | Miss |
| Jun 29, 2026 | – | $0.06 | |
| Mar 16, 2026 | – | $0.04 | |
| Dec 29, 2025 | – | $0.06 | |
| Sep 18, 2025 | – | $0.08 | |
| Jun 26, 2025 | – | $0.07 |